Nabsys Partners with Hitachi to Enhance Hematologic Malignancies Research Using OhmX Technology

Nabsys and Hitachi's Collaborative Leap in Hematological Research

Nabsys 2.0, LLC, a pioneer in electronic genome mapping (EGM) technology, has entered into a strategic partnership with Hitachi High-Tech America (HTA) to advance research in hematologic malignancies. The collaboration is part of the OhmX™ Rapid Application to Market Penetration User Partnership (RAMP UP) program, designed to support transformative applications in the study of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Leading the charge is Brynn Levy, M.Sc.(Med)., Ph.D., FACMG, a distinguished cytogeneticist and Professor at Columbia University Vagelos College of Physicians and Surgeons. Known for his expertise, Dr. Levy will utilize his lab as a critical hub for research under the RAMP UP program, facilitating groundbreaking studies in hematologic conditions.

Understanding the Importance of Electronic Genome Mapping

The OhmX Platform is designed to tackle critical gaps in current cytogenetic approaches that often limit the understanding of genomic interactions within leukemia and other hematologic disorders. Traditional methods like Fluorescence In Situ Hybridization (FISH) focus on a limited set of genetic loci and tend to provide subjective evaluations at lower resolution through karyotyping. Conversely, genome-wide technologies tend to present their own set of complexities that can be challenging to navigate, especially for focused investigations of specific disease-related regions.

The innovative approach of the OhmX Platform allows for comprehensive, high-resolution analysis of ultra-long DNA molecules. This enables profound insights into structural variants through electronic detection using a nanochannel-based architecture, ultimately facilitating efficient integration of broader copy number variations (CNVs) within established cytogenetics workflows.

A Breakthrough in Research Applications

The primary objective of this collaboration between Nabsys and HTA is to enable detailed analysis of structural variants in known leukemia driver loci. With leukemia strongly influenced by structural abnormalities, this initiative will empower researchers to gain new perspectives on genomic changes at clinically relevant loci. Not only does this facilitate deeper comprehension of genetic variations, but it also serves as a valuable resource for cohort-based studies and translational research.

Dr. Levy expressed his enthusiasm for the initiative, stating, "I'm delighted to join the RAMP UP program with Nabsys and HTA. The significance of structural variations in diseases such as AML and MDS cannot be understated. Access to next-generation tools with high-resolution capabilities is crucial for enabling new types of translational research."

The Benefits of Collaboration

Highlighting the importance of specialized research in targeted therapies for hematologic malignancies, Brian Buckingham, HTA's President and CEO, stated, "Effective treatments must align with the unique manifestations of diseases like AML and MDS. We aim to fill this gap with insights fueled by EGM, essential in shaping innovative therapeutic approaches."

This partnership represents a paradigm shift, bringing together advanced EGM technology and clinical expertise. Nabsys sees great potential in this collaborative effort, further driven by the wealth of experience Dr. Levy brings as a leading cytogeneticist. Barrett Bready, M.D., Founder and CEO of Nabsys, underscored the aim of this collaboration, emphasizing how EGM technology could redefine cancer research outcomes.

Engaging at the American Cytogenetics Conference

As part of their commitment to advancing genomics research, the Nabsys team will be showcasing their progress at the prestigious American Cytogenetics Conference (ACC) in San Diego, California, from May 17 to 20, 2026. Presenting on the OhmX Platform and its ongoing applications, they aim to engage the wider scientific community about this transformative technology. The company will hold a platform presentation focused on CRISPR-assisted electronic genome mapping, further displaying the versatility and potential of the OhmX technology in translational studies.

Nabsys continues to reinforce its commitment to transforming genomic research with its proprietary EGM technology encapsulated in the OhmX Platform, designed to empower researchers worldwide in accessing critical insights and unlocking structural information on a genomic scale. With an eye on the future, the implications of this partnership sit at the forefront of hematologic malignancy research, paving the way for novel therapeutic developments that can impact patient outcomes significantly.

For more information about Nabsys and its advanced EGM capabilities, visit Nabsys website.